Literature DB >> 11445735

Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis.

B W Grinnell1, D Joyce.   

Abstract

OBJECTIVE: To review the mechanisms of action and rationale for the use of recombinant human activated protein C in the treatment of severe sepsis. Specifically, we focus on the mechanisms of action in the protein C pathway that converge to modulate the pathophysiology of severe inflammatory disease and sepsis. This analysis includes a discussion of the role of activated protein C in directly modulating cell system biology, independent of antithrombotic activity. DATA SOURCES/STUDY SELECTION: Published research and review articles relating to the protein C pathway, recombinant human protein C, and the role of protein C in sepsis. Data were also derived from broad gene profiling in model systems of endothelial dysfunction. DATA EXTRACTION AND SYNTHESIS: Relevant studies were included to support discussion of the unique mechanistic aspect of protein C and its role in the pathogenesis of severe sepsis. We discuss the potential of activated protein C as a unique system modulator for the treatment of severe sepsis and other systemic inflammatory responses that result in microvascular coagulopathy, endothelial dysfunction, and vascular bed failure.
CONCLUSIONS: The protein C pathway plays a unique role in modulating vascular function. As an antithrombotic/profibrinolytic agent, it plays a clear role in maintaining vascular patency. Moreover, it has anti-inflammatory properties and appears to play a unique role as an antiapoptotic and endothelial cell survival factor. In states of systemic inflammatory activation, loss of protein C due to consumptive processes results in a compromised ability to modulate coagulation as well as inflammatory and cell survival functions. This compromise leads to vascular dysfunction, end-organ failure, and death. Replacement with recombinant human activated protein C offers a system-modulating approach to improved outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445735     DOI: 10.1097/00003246-200107001-00020

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  15 in total

Review 1.  Emerging therapies in severe sepsis.

Authors:  S J Finney; T W Evans
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

2.  Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Authors:  Thomas E Ichim; Boris Minev; Todd Braciak; Brandon Luna; Ron Hunninghake; Nina A Mikirova; James A Jackson; Michael J Gonzalez; Jorge R Miranda-Massari; Doru T Alexandrescu; Constantin A Dasanu; Vladimir Bogin; Janis Ancans; R Brian Stevens; Boris Markosian; James Koropatnick; Chien-Shing Chen; Neil H Riordan
Journal:  J Transl Med       Date:  2011-03-04       Impact factor: 5.531

3.  Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial.

Authors:  Jean-François Dhainaut; Pierre-François Laterre; Jonathan M Janes; Gordon R Bernard; Antonio Artigas; Jan Bakker; Hanno Riess; Bruce R Basson; Julien Charpentier; Barbara G Utterback; Jean-Louis Vincent
Journal:  Intensive Care Med       Date:  2003-04-24       Impact factor: 17.440

Review 4.  Progress in the understanding of the protein C anticoagulant pathway.

Authors:  Björn Dahlbäck
Journal:  Int J Hematol       Date:  2004-02       Impact factor: 2.490

5.  Distinct functions of activated protein C differentially attenuate acute kidney injury.

Authors:  Akanksha Gupta; Bruce Gerlitz; Mark A Richardson; Christopher Bull; David T Berg; Samreen Syed; Elizabeth J Galbreath; Barbara A Swanson; Bryan E Jones; Brian W Grinnell
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

6.  IKKβ regulates endothelial thrombomodulin in a Klf2-dependent manner.

Authors:  R Pathak; L Shao; D Zhou; M Hauer-Jensen; S M Chafekar; W Feng; U Ponnappan; L M Fink
Journal:  J Thromb Haemost       Date:  2014-08-11       Impact factor: 5.824

7.  An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures.

Authors:  Madeline Betancourt; Peggy S McKinnon; R Michael Massanari; Salmaan Kanji; David Bach; John W Devlin
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

8.  Crucial role of the protein C pathway in governing microvascular inflammation in inflammatory bowel disease.

Authors:  Franco Scaldaferri; Miquel Sans; Stefania Vetrano; Cristina Graziani; Raimondo De Cristofaro; Bruce Gerlitz; Alessandro Repici; Vincenzo Arena; Alberto Malesci; Julian Panes; Brian W Grinnell; Silvio Danese
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 9.  Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.

Authors:  S M Pastores
Journal:  Postgrad Med J       Date:  2003-01       Impact factor: 2.401

10.  FoxA2 involvement in suppression of protein C, an outcome predictor in experimental sepsis.

Authors:  David T Berg; Bruce Gerlitz; Ganesh R Sharma; Mark A Richardson; Eddie J Stephens; Renee L Grubbs; Kimberly C Holmes; Kelly Fynboe; Dominick Montani; Martin S Cramer; Steven D Engle; Joseph A Jakubowski; Josef G Heuer; Brian W Grinnell
Journal:  Clin Vaccine Immunol       Date:  2006-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.